Difference between revisions of "Toripalimab (Loqtorzi)"
Jump to navigation
Jump to search
m |
m |
||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| Line 9: | Line 8: | ||
*[[Non-small cell lung cancer, nonsquamous]] | *[[Non-small cell lung cancer, nonsquamous]] | ||
*[[Non-small cell lung cancer, squamous]] | *[[Non-small cell lung cancer, squamous]] | ||
| − | + | *[[Urothelial carcinoma]] | |
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
*2018-12-17: Initial approval | *2018-12-17: Initial approval | ||
| Line 21: | Line 20: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| − | |||
[[Category:Esophageal squamous cell carcinoma medications]] | [[Category:Esophageal squamous cell carcinoma medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
| Line 27: | Line 25: | ||
[[Category:Non-small cell lung cancer, nonsquamous medications]] | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
| + | [[Category:Urothelial carcinoma medications]] | ||
[[Category:NMPA approved in 2018]] | [[Category:NMPA approved in 2018]] | ||
Revision as of 13:31, 9 September 2023
Mechanism of action
From the NCI Drug Dictionary: A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
- Esophageal squamous cell carcinoma
- Melanoma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer, nonsquamous
- Non-small cell lung cancer, squamous
- Urothelial carcinoma
History of changes in NMPA indication
- 2018-12-17: Initial approval
Also known as
- Code names: JS-001, TAB-001
- Generic name: teriprolizumab
- Brand name: Tuoyi
Categories:
- Drugs
- Intravenous medications
- Anti-PD-1 antibodies
- Esophageal squamous cell carcinoma medications
- Melanoma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer, nonsquamous medications
- Non-small cell lung cancer, squamous medications
- Urothelial carcinoma medications
- NMPA approved in 2018